Data from a randomised extension study showed that patients with moderate-to-severe plaque psoriasis attained durable complete and near-complete responses for more than a year with a dual inhibitor of IL-17 .
Both IL-17A and IL-17F are expressed in psoriasis lesional skin and have the ability to synergise with other cytokines to amplify inflammation. This is the pathogenetic rationale to block IL-17F in addition to IL-17A. Bimekizumab is an antibody that neutralises the biologic function of both.
In the original 12-week BE ABLE 1 study previously presented, therapy with bimekizumab led to rapid, substantial clinical improvements in patients with moderate-to-severe plaque psoriasis . More than 70% of patients treated with 160, 320, or 480 mg bimekizumab reached an improvement of the PASI by 90% (PASI90 response) in this trial. At this year´s AAD meeting, results were presented of the phase 2b extension study BE ABLE 2 after 60 weeks of follow-u...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Pemphigus patients prone to osteoporosis Next Article
Plaque psoriasis – Efficacy of guselkumab »